Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fulzerasib + cetuximab beta
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
fulzerasib + Enlituo is a combination therapy consisting of fulzerasib (Dupert), an orally active, selective, covalent, and irreversible small-molecule inhibitor of the KRAS G12C mutant protein, and Enlituo (cetuximab beta), a recombinant epidermal growth factor receptor (EGFR) monoclonal antibody. Developed through a collaboration involving GenFleet Therapeutics, Mabpharm, Innovent Biologics, and Simcere Zaiming, this combination is designed to overcome resistance to KRAS G12C inhibition. KRAS inhibition often triggers feedback reactivation of the EGFR pathway, and combining it with an anti-EGFR antibody like cetuximab beta synergistically blocks downstream MAPK signaling, enhancing antitumor efficacy. The combination is currently being evaluated in Phase II clinical trials for the treatment of KRAS G12C-mutated metastatic colorectal cancer (mCRC) and untreated advanced non-small cell lung cancer (NSCLC).
- Brand names
- Dupert
- Other names
- cetuximab beta + fulzerasibCMAB009 + GFH925CMAB009 + IBI351fulzerasib + cetuximab betafulzerasib + EnlituoGFH925 + cetuximab betaGFH925 + EnlituoIBI351 + cetuximab betaIBI351 + CMAB009IBI351 + Enlituo
02
Targets
EGFR (Epidermal growth factor receptor)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)
Beyond the preview
Go deeper on fulzerasib + cetuximab beta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fulzerasib + cetuximab beta.